Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 378

1.

Fremanezumab for the preventive treatment of migraine.

Silberstein SD, Cohen JM, Yeung PP.

Expert Opin Biol Ther. 2019 Jun 10. doi: 10.1080/14712598.2019.1627323. [Epub ahead of print]

PMID:
31177856
2.

Early onset of effect of onabotulinumtoxinA for chronic migraine treatment: Analysis of PREEMPT data.

Dodick DW, Silberstein SD, Lipton RB, DeGryse RE, Adams AM, Diener HC.

Cephalalgia. 2019 May 21:333102418825382. doi: 10.1177/0333102418825382. [Epub ahead of print]

PMID:
31112399
3.

Vestibular Neuroscience for the Headache Specialist.

Balaban CD, Black RD, Silberstein SD.

Headache. 2019 May 11. doi: 10.1111/head.13550. [Epub ahead of print]

PMID:
31077365
4.

Remote Electrical Neuromodulation (REN) Relieves Acute Migraine: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial.

Yarnitsky D, Dodick DW, Grosberg BM, Burstein R, Ironi A, Harris D, Lin T, Silberstein SD.

Headache. 2019 May 9. doi: 10.1111/head.13551. [Epub ahead of print]

PMID:
31074005
5.

Safety and Tolerability of Fremanezumab for the Prevention of Migraine: A Pooled Analysis of Phases 2b and 3 Clinical Trials.

Silberstein SD, McAllister P, Ning X, Faulhaber N, Lang N, Yeung P, Schiemann J, Aycardi E, Cohen JM, Janka L, Yang R.

Headache. 2019 Jun;59(6):880-890. doi: 10.1111/head.13534. Epub 2019 Apr 12.

PMID:
30977520
6.

The endocannabinoid system in migraine: from bench to pharmacy and back.

Tassorelli C, Greco R, Silberstein SD.

Curr Opin Neurol. 2019 Jun;32(3):405-412. doi: 10.1097/WCO.0000000000000688.

PMID:
30883435
7.

Current Status of Antiepileptic Drugs as Preventive Migraine Therapy.

Parikh SK, Silberstein SD.

Curr Treat Options Neurol. 2019 Mar 18;21(4):16. doi: 10.1007/s11940-019-0558-1. Review.

PMID:
30880369
8.

Invited Commentary on Preventive Anti-Migraine Therapy (PAMT).

Jain S, Silberstein SD.

Curr Treat Options Neurol. 2019 Mar 14;21(4):14. doi: 10.1007/s11940-019-0555-4. Review.

PMID:
30868470
9.

Development of a claims-based algorithm to identify potentially undiagnosed chronic migraine patients.

Pavlovic JM, Yu JS, Silberstein SD, Reed ML, Kawahara SH, Cowan RP, Dabbous F, Campbell KL, Shewale AR, Pulicharam R, Kowalski JW, Viswanathan HN, Lipton RB.

Cephalalgia. 2019 Apr;39(4):465-476. doi: 10.1177/0333102418825373. Epub 2019 Mar 9.

PMID:
30854881
10.

Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition.

Diener HC, Tassorelli C, Dodick DW, Silberstein SD, Lipton RB, Ashina M, Becker WJ, Ferrari MD, Goadsby PJ, Pozo-Rosich P, Wang SJ, Mandrekar J; International Headache Society Clinical Trials Standing Committee.

Cephalalgia. 2019 May;39(6):687-710. doi: 10.1177/0333102419828967. Epub 2019 Feb 26.

11.

Calcitonin Gene-Related Peptide Antagonists in the Treatment of Episodic Migraine.

Yuan H, White CS, Silberstein SD.

Clin Pharmacol Ther. 2019 May;105(5):1121-1129. doi: 10.1002/cpt.1356. Epub 2019 Mar 18.

PMID:
30648737
12.

The Effect of Beginning Treatment With Fremanezumab on Headache and Associated Symptoms in the Randomized Phase 2 Study of High Frequency Episodic Migraine: Post-Hoc Analyses on the First 3 Weeks of Treatment.

Silberstein SD, Rapoport AM, Loupe PS, Aycardi E, McDonald M, Yang R, Bigal ME.

Headache. 2019 Mar;59(3):383-393. doi: 10.1111/head.13446. Epub 2018 Nov 18.

PMID:
30450545
13.

Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study.

Kuca B, Silberstein SD, Wietecha L, Berg PH, Dozier G, Lipton RB; COL MIG-301 Study Group.

Neurology. 2018 Dec 11;91(24):e2222-e2232. doi: 10.1212/WNL.0000000000006641. Epub 2018 Nov 16.

14.

Basic Considerations for the Use of Monoclonal Antibodies in Migraine.

Levin M, Silberstein SD, Gilbert R, Lucas S, Munsie L, Garrelts A, Kennedy K, Everman N, Pearlman E.

Headache. 2018 Nov;58(10):1689-1696. doi: 10.1111/head.13439. Epub 2018 Nov 13.

15.

Health care Resource Utilization and Migraine Disability Along the Migraine Continuum Among Patients Treated for Migraine.

Silberstein SD, Lee L, Gandhi K, Fitzgerald T, Bell J, Cohen JM.

Headache. 2018 Nov;58(10):1579-1592. doi: 10.1111/head.13421. Epub 2018 Oct 30.

PMID:
30375650
16.

From LBR-101 to Fremanezumab for Migraine.

Bigal ME, Rapoport AM, Silberstein SD, Walter S, Hargreaves RJ, Aycardi E.

CNS Drugs. 2018 Nov;32(11):1025-1037. doi: 10.1007/s40263-018-0579-4. Review.

PMID:
30311143
17.

Erenumab in the treatment of migraine.

Jain S, Yuan H, Spare N, Silberstein SD.

Pain Manag. 2018 Nov 1;8(6):415-426. doi: 10.2217/pmt-2018-0037. Epub 2018 Sep 21. Review.

PMID:
30235976
18.

Rationale for electrical parameter determination in external trigeminal nerve stimulation (eTNS) for migraine: A narrative review.

Lauritsen CG, Silberstein SD.

Cephalalgia. 2019 May;39(6):750-760. doi: 10.1177/0333102418796781. Epub 2018 Aug 23.

PMID:
30139273
19.

Ketamine for Refractory Headache: A Retrospective Analysis.

Schwenk ES, Dayan AC, Rangavajjula A, Torjman MC, Hernandez MG, Lauritsen CG, Silberstein SD, Young W, Viscusi ER.

Reg Anesth Pain Med. 2018 Nov;43(8):875-879. doi: 10.1097/AAP.0000000000000827.

PMID:
29923953
20.

Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial.

Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y, Aycardi E.

JAMA. 2018 May 15;319(19):1999-2008. doi: 10.1001/jama.2018.4853.

PMID:
29800211
21.

The Use and Method of Action of Intravenous Lidocaine and Its Metabolite in Headache Disorders.

Berk T, Silberstein SD.

Headache. 2018 May;58(5):783-789. doi: 10.1111/head.13298. Epub 2018 Mar 14.

PMID:
29536530
22.

A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study).

Starling AJ, Tepper SJ, Marmura MJ, Shamim EA, Robbins MS, Hindiyeh N, Charles AC, Goadsby PJ, Lipton RB, Silberstein SD, Gelfand AA, Chiacchierini RP, Dodick DW.

Cephalalgia. 2018 May;38(6):1038-1048. doi: 10.1177/0333102418762525. Epub 2018 Mar 4.

23.

Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults.

Tassorelli C, Diener HC, Dodick DW, Silberstein SD, Lipton RB, Ashina M, Becker WJ, Ferrari MD, Goadsby PJ, Pozo-Rosich P, Wang SJ; International Headache Society Clinical Trials Standing Committee.

Cephalalgia. 2018 Apr;38(5):815-832. doi: 10.1177/0333102418758283. Epub 2018 Mar 4.

PMID:
29504482
24.

Preventive Therapies for Chronic Migraine.

Silberstein SD, Yeung PP, Aycardi E.

N Engl J Med. 2018 Feb 22;378(8):774. doi: 10.1056/NEJMc1716990. No abstract available.

PMID:
29466162
25.

Current management: migraine headache.

Silberstein SD.

CNS Spectr. 2017 Dec;22(S1):1-13. doi: 10.1017/S1092852917000864.

PMID:
29350125
26.

Percutaneous Closure of Patent Foramen Ovale in Patients With Migraine: The PREMIUM Trial.

Tobis JM, Charles A, Silberstein SD, Sorensen S, Maini B, Horwitz PA, Gurley JC.

J Am Coll Cardiol. 2017 Dec 5;70(22):2766-2774. doi: 10.1016/j.jacc.2017.09.1105.

27.

Fremanezumab for the Preventive Treatment of Chronic Migraine.

Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y, Aycardi E.

N Engl J Med. 2017 Nov 30;377(22):2113-2122. doi: 10.1056/NEJMoa1709038.

28.

The emerging role of gammaCore® in the management of cluster headache: expert panel recommendations.

Silberstein SD, Calhoun AH, Treppendahl C, Dodick DW, Rapoport AM, Mamidi A, Vargas P, Ebert TH, Tepper SJ.

Am J Manag Care. 2017 Nov;23(17 Suppl):S326-S333.

29.

CGRP Monoclonal Antibodies for Migraine: Rationale and Progress.

Yuan H, Lauritsen CG, Kaiser EA, Silberstein SD.

BioDrugs. 2017 Dec;31(6):487-501. doi: 10.1007/s40259-017-0250-5. Review.

PMID:
29116598
30.

AVP-825 (Sumatriptan Nasal Powder) Reduces Nausea Compared to Sumatriptan Tablets: Results of the COMPASS Randomized Clinical Trial.

Lipton RB, McGinley JS, Shulman KJ, Silberstein SD, Wirth RJ, Buse DC.

Headache. 2018 Feb;58(2):229-242. doi: 10.1111/head.13199. Epub 2017 Oct 16.

PMID:
29034453
31.

A review of clinical safety data for sumatriptan nasal powder administered by a breath powered exhalation delivery system in the acute treatment of migraine.

Silberstein SD.

Expert Opin Drug Saf. 2018 Jan;17(1):89-97. doi: 10.1080/14740338.2018.1390563. Epub 2017 Oct 20. Review.

PMID:
28994319
32.

Histamine and Migraine.

Yuan H, Silberstein SD.

Headache. 2018 Jan;58(1):184-193. doi: 10.1111/head.13164. Epub 2017 Sep 1. Review.

PMID:
28862769
33.

Neuropeptides.

Silberstein SD.

Headache. 2017 May;57 Suppl 2:35-36. doi: 10.1111/head.13093. No abstract available.

PMID:
28485847
34.

Insights into the Functional Anatomy Behind the PREEMPT Injection Paradigm: Guidance on Achieving Optimal Outcomes.

Blumenfeld AM, Silberstein SD, Dodick DW, Aurora SK, Brin MF, Binder WJ.

Headache. 2017 May;57(5):766-777. doi: 10.1111/head.13074. Epub 2017 Apr 6.

35.

Topiramate in Migraine Prevention: A 2016 Perspective.

Silberstein SD.

Headache. 2017 Jan;57(1):165-178. doi: 10.1111/head.12997. Epub 2016 Nov 30. Review.

PMID:
27902848
36.

Non-Invasive Vagus Nerve Stimulation for the ACute Treatment of Cluster Headache: Findings From the Randomized, Double-Blind, Sham-Controlled ACT1 Study.

Silberstein SD, Mechtler LL, Kudrow DB, Calhoun AH, McClure C, Saper JR, Liebler EJ, Rubenstein Engel E, Tepper SJ; ACT1 Study Group.

Headache. 2016 Sep;56(8):1317-32. doi: 10.1111/head.12896.

37.

The American Headache Society Cluster Guidelines.

Silberstein SD.

Headache. 2016 Jul;56(7):1091-2. doi: 10.1111/head.12867. No abstract available.

PMID:
27432622
38.

Chronic migraine headache prevention with noninvasive vagus nerve stimulation: The EVENT study.

Silberstein SD, Calhoun AH, Lipton RB, Grosberg BM, Cady RK, Dorlas S, Simmons KA, Mullin C, Liebler EJ, Goadsby PJ, Saper JR; EVENT Study Group.

Neurology. 2016 Aug 2;87(5):529-38. doi: 10.1212/WNL.0000000000002918. Epub 2016 Jul 13.

39.

The migraine postdrome: An electronic diary study.

Giffin NJ, Lipton RB, Silberstein SD, Olesen J, Goadsby PJ.

Neurology. 2016 Jul 19;87(3):309-13. doi: 10.1212/WNL.0000000000002789. Epub 2016 Jun 22.

40.

Considerations for management of migraine symptoms in the primary care setting.

Silberstein SD.

Postgrad Med. 2016 Jun;128(5):523-37. doi: 10.1080/00325481.2016.1175912. Epub 2016 May 10. Review.

PMID:
27078039
41.

Erratum to: Targeting CGRP: A New Era for Migraine Treatment.

Wrobel Goldberg S, Silberstein SD.

CNS Drugs. 2016 Apr;30(4):355. No abstract available.

PMID:
27067342
42.

The Use of Botulinum Toxin in the Management of Headache Disorders.

Silberstein SD.

Semin Neurol. 2016 Feb;36(1):92-8. doi: 10.1055/s-0036-1571443. Epub 2016 Feb 11.

PMID:
26866501
43.

Long-Term Pain Reduction Does Not Imply Improved Functional Outcome in Patients Treated With Combined Supraorbital and Occipital Nerve Stimulation for Chronic Migraine.

Clark SW, Wu C, Boorman DW, Chalouhi N, Zanaty M, Oshinsky M, Young WB, Silberstein SD, Sharan AD.

Neuromodulation. 2016 Jul;19(5):507-14. doi: 10.1111/ner.12400. Epub 2016 Feb 10.

PMID:
26861893
44.

Single-item migraine screening tests, self-reported bothersome headache or stripe pattern hypersensitivity?

Yuan H, Hopkins M, Goldberg JD, Silberstein SD.

Acta Neurol Scand. 2016 Oct;134(4):277-83. doi: 10.1111/ane.12539. Epub 2015 Dec 1.

PMID:
26626126
45.

Vagus Nerve Stimulation and Headache.

Yuan H, Silberstein SD.

Headache. 2017 Apr;57 Suppl 1:29-33. doi: 10.1111/head.12721. Epub 2015 Oct 16. Review.

PMID:
26473407
46.

Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.

Bigal ME, Dodick DW, Rapoport AM, Silberstein SD, Ma Y, Yang R, Loupe PS, Burstein R, Newman LC, Lipton RB.

Lancet Neurol. 2015 Nov;14(11):1081-90. doi: 10.1016/S1474-4422(15)00249-5. Epub 2015 Sep 30.

PMID:
26432182
47.

Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.

Bigal ME, Edvinsson L, Rapoport AM, Lipton RB, Spierings EL, Diener HC, Burstein R, Loupe PS, Ma Y, Yang R, Silberstein SD.

Lancet Neurol. 2015 Nov;14(11):1091-100. doi: 10.1016/S1474-4422(15)00245-8. Epub 2015 Sep 30.

PMID:
26432181
48.

Vagus Nerve and Vagus Nerve Stimulation, a Comprehensive Review: Part II.

Yuan H, Silberstein SD.

Headache. 2016 Feb;56(2):259-66. doi: 10.1111/head.12650. Epub 2015 Sep 18. Review.

PMID:
26381725
49.

Vagus Nerve and Vagus Nerve Stimulation, a Comprehensive Review: Part III.

Yuan H, Silberstein SD.

Headache. 2016 Mar;56(3):479-90. doi: 10.1111/head.12649. Epub 2015 Sep 14. Review.

PMID:
26364805
50.

Vagus Nerve and Vagus Nerve Stimulation, a Comprehensive Review: Part I.

Yuan H, Silberstein SD.

Headache. 2016 Jan;56(1):71-8. doi: 10.1111/head.12647. Epub 2015 Sep 14. Review.

PMID:
26364692

Supplemental Content

Loading ...
Support Center